Regression estimates and incidence rate ratios from GLMER for number of papers (top) and coauthors (bottom). by William C. Barley (8915282)

Subjects:

Fig 1B raw image. by Rachel K. Meade (22216529)

Subjects:

S1A Fig raw image. by Rachel K. Meade (22216529)

Subjects:

Identification and validation of <i>Ctsz</i> as the lead candidate gene underlying <i>Tip5.</i> by Rachel K. Meade (22216529)

Subjects:

Supplementary Material for: Adjunctive active vitamin D (AVD) decreases kidney function during treatment of secondary hyperparathyroidism (SHPT) with extended-release calcifediol (... by figshare admin karger (2628495)

Fig 6 - by Kirralise J. Hansford (20670869)

Subjects:

Comparison of Analgesic Consumption by WHO Analgesic Level Between 2023 and 2022. by Myriam Aïche (22290591)

Subjects:

The properties of dental materials: Purpose of usage, manufacturer, composition, setting type and setting time. by Meltem Karahan (19713246)

Subjects:

Dose-dependent effect of dental materials on hatching rate of zebrafish embryos and larvae at the indicated time points. by Meltem Karahan (19713246)

Subjects:

Multivariate Linear Regression Analysis of Factors Associated with Pain Scores (VAS) in Children Aged 7–12. by Myriam Aïche (22290591)

Subjects:

Flow chart. by Myriam Aïche (22290591)

Subjects:

Dose-dependent effect of dental materials on the survival of zebrafish embryos and larvae at the indicated time points. by Meltem Karahan (19713246)

Subjects:

Determination of Cleaved Caspase-3 positive cells in MTA and Harvard treated groups. by Meltem Karahan (19713246)

Subjects:

The apoptic effects of dental materials on zebrafish larvae. by Meltem Karahan (19713246)

Subjects:

Linear regression. by Myriam Aïche (22290591)

Subjects:

Comparison of Pain Scores (VAS) Between Children Exposed and Not Exposed to the Fear Self-Assessment Tool (Trouillomètre®). by Myriam Aïche (22290591)

Subjects:

Blood Pressure and LDL-C During Follow-up. by Karl Ingard (22582091)

Subjects:

Median EQ-5D-3L index values during 5 years of follow-up. by Karl Ingard (22582091)

Subjects:

Baseline Characteristics of Included Patients. by Karl Ingard (22582091)

Subjects:

Subgroup Analysis of the Occurrence of Secondary Endpoints. by Karl Ingard (22582091)

Subjects: